OSIR blindsided by SNY: http://finance.yahoo.com/news/Osiris-Therapeutics-Provides-bw-1064388524.html?x=0 On Wednesday, February 8, 2012, Sanofi issued a press release, which included an update on their R&D pipeline, stating that it has "discontinued" its project with Prochymal for graft versus host disease. The statement issued by Sanofi was made without consultation with or knowledge of Osiris. Osiris has not received any notification from Sanofi regarding the discontinuation of the agreement in place between the two companies. Did someone at OSIR forget to leave the fax on?